logo-loader

Scancell recruits final patient in melanoma trial

Last updated: 03:02 29 Jan 2013 EST, First published: 04:02 29 Jan 2013 EST

no_picture_pai

 

Cancer drug specialist Scancell Holdings (LON:SCLP) has treated the final patient in the second part of a phase 1/2 clinical trial of SCIB1, its potential vaccine for melanoma.

Shares in Scancell were AIM’s best performers last year, with enthusiam fuelled by excitement over the potential of SCIB1.

The trial is currently being conducted in five UK centres in patients with Stage III/IV disease to further assess its safety and the cellular immune response induced by SCIB1.

Patients are being treated with a 4 milligram (mg) dose on five occasions over a period of six months. In December, the company also received approval to dose an extra group of patients with a higher, 8 mg, dose of SCIB1.

Dr Richard Goodfellow, joint chief executive of Scancell, said: "The SCIB1 clinical programme is progressing on schedule and, as previously announced, we expect the results for Part 2 of the study to be available by the end of 2013.”

In December, Scancell released preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response that might be associated with clinical benefit in patients with malignant melanoma.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 - a type of white blood cell that fights infection - that destroy tumours without toxicity. The company believes could have a profound effect on the way that cancer vaccines are developed.

 

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023